G2B-002 / Shilpa Medicare, Gate2Brain - LARVOL DELTA

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy (Businesswire) - "Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 - Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28."

First-in-human • Licensing / partnership • New trial • Diffuse Intrinsic Pontine Glioma • Glioblastoma